addit
sensit
specif
assay
assess
neutral
antibodi
activ
clinic
trial
sampl
must
amen
autom
use
highvolum
screen
effect
develop
micropl
assay
measur
hcmvneutral
activ
human
sera
use
hcmvpermiss
human
cell
line
laboratori
strain
hcmv
degre
neutral
antibodi
diminish
hcmv
infect
cell
assay
determin
quantifi
nuclei
infect
cell
base
express
kda
viral
protein
nuclear
visual
use
highli
sensit
immunoperoxidas
stain
stain
nuclei
count
use
autom
elispot
analyz
use
half
area
micropl
well
surfac
area
well
bottom
half
area
standard
micropl
plate
improv
signal
detect
compar
standard
micropl
econom
usag
indic
cell
viru
reagent
stain
process
also
streamlin
use
micropl
washer
data
analysi
simplifi
acceler
employ
softwar
program
automat
plot
neutral
curv
determin
nt
valu
use
curv
fit
optim
assay
fast
conveni
also
specif
sensit
precis
reproduc
thu
characterist
necessari
use
measur
hcmvneutral
activ
sera
vaccin
trial
subject
recipi
vical
hcmv
pdna
vaccin
candid
humor
immun
play
signific
role
control
hcmv
infect
diseas
man
hcmvneutral
antibodi
interfer
receptormedi
viru
entri
suscept
cell
hcmv
gb
shown
major
target
neutral
antibodi
induc
natur
acquir
infect
britt
et
al
gonczol
et
al
marshal
et
al
although
antigen
bind
elisa
measur
antibodi
specif
hcmv
antigen
gb
protein
assay
neutral
viral
entri
cell
measur
establish
quantifi
biolog
activ
hcmv
antigen
specif
antibodi
goal
develop
hcmv
microneutr
assay
suitabl
screen
larg
number
serum
sampl
vaccin
clinic
trial
vical
current
test
hcmv
pdna
vaccin
candid
encod
ectodomain
gb
pdna
vaccin
shown
induc
specif
antibodi
respons
measur
elisa
anim
selinski
et
al
human
wloch
prepar
quantif
hcmvneutral
antibodi
titrat
hcmv
stock
often
reli
tediou
long
plaqu
assay
base
cytopath
effect
viru
lantto
et
al
andreoni
et
al
nejatollahi
et
al
mitchel
et
al
avail
mab
specif
earli
gene
product
hcmv
enabl
develop
assay
detect
hcmv
infect
much
faster
gleav
et
al
griffith
et
al
alpert
first
overnight
assay
detect
hcmv
infect
measur
neutral
use
cluster
plate
fibroblast
indic
monolay
commerci
mab
specif
hcmv
iea
coupl
immunoperoxidas
stain
detect
cell
infect
hcmv
lab
strain
clinic
cmv
isol
chou
scott
first
rapid
hcmv
neutral
assay
develop
micropl
andreoni
et
al
use
immunofluoresc
stain
infect
cell
iea
requir
manual
count
stain
nuclei
fluoresc
microscop
although
micropl
format
enabl
simultan
test
multipl
sampl
assay
endpoint
reach
within
h
manual
count
label
imag
make
techniqu
slow
tediou
thu
limit
small
scale
use
use
iea
expressionbas
detect
micropl
format
develop
sensit
specif
immunohistochem
stain
procedur
enabl
us
quantifi
infect
cell
elispot
analyz
autom
data
analysi
employ
curv
fit
softwar
streamlin
assay
made
determin
neutral
activ
simpl
quick
object
improv
assay
select
optim
assay
plate
type
robust
indic
cell
line
optimum
assay
condit
better
distinct
neutral
nonneutr
sera
result
extens
qualif
run
show
novel
hcmv
microneutr
assay
specif
sensit
linear
precis
reproduc
expect
cellbas
bioassay
intend
use
clinic
trial
human
embryon
fibroblastlik
cell
line
obtain
american
type
cultur
collect
atcc
manassa
va
cultiv
atcc
minim
essenti
medium
supplement
fb
hyclon
logan
ut
gradientpurifi
infecti
hcmv
purchas
advanc
biotechnolog
incorpor
abi
columbia
md
viru
stock
viru
particlesml
dilut
fb
store
aliquot
use
human
sera
code
anonym
obtain
healthi
adult
hcmvseroneg
seroposit
individu
includ
hcmvseroneg
subject
vical
phase
clinic
trial
develop
serum
antigb
igg
respons
result
vaccin
cmv
dna
vaccin
vical
inhous
volunt
inform
consent
obtain
subject
natur
possibl
consequ
studi
fulli
explain
pool
ab
serum
ab
pool
purchas
pelfreez
biolog
roger
ar
sera
classifi
hcmvseroposit
hcmvseroneg
base
reactiv
commerci
hcmv
igg
elisa
diamedix
miami
fl
analyz
gbspecif
serum
igg
level
indirect
gbbind
elisa
develop
vical
wloch
unpublish
data
neg
sera
well
sera
gb
elisa
titer
rang
chosen
neutral
analysi
sera
antigb
igg
titer
least
natur
hcmvseroposit
individu
wherea
sera
titer
origin
hcmvseroneg
vaccine
nsc
prepar
combin
sera
three
nonvaccin
hcmvseroneg
individu
serum
singl
volunt
donor
gb
elisa
titer
use
psc
sera
store
aliquot
use
freezedri
gpsc
purchas
equitechbio
inc
kerrvil
tx
store
reconstitut
use
precipit
peroxidas
substrat
histomark
black
cobalt
enhanc
dab
stabledab
stabil
twocompon
dab
trueblu
buffer
solut
tmb
h
purchas
kpl
gaithersburg
md
wherea
aec
purchas
vector
laboratori
burlingam
ca
day
initi
assay
cell
prepar
cellsml
rpmihep
gibcoinvitrogen
carlsbad
ca
supplement
fb
hyclon
logan
ut
seed
either
cell
per
well
standard
wellsiz
nunc
brand
cell
per
well
corningcostar
brand
half
area
flat
bottom
tissu
cultur
micropl
fisher
scientif
pittsburgh
pa
day
one
test
sera
serial
dilut
twofold
sixtoeight
time
rpmihep
medium
contain
psf
uml
penicillin
g
streptomycin
sulfat
amphotericin
b
gibcoinvitrogen
carlsbad
ca
either
fb
gpsc
fetal
bovin
serum
gpsc
human
control
test
sera
use
without
heat
inactiv
endogen
complement
activ
min
note
viru
stock
thaw
ice
gentli
resuspend
dilut
rpmihep
contain
psf
fb
per
well
ad
serial
dilut
human
sera
incub
h
viru
dilut
yield
sever
hundr
infect
cell
per
well
absenc
neutral
activ
cultur
medium
care
aspir
assay
plate
replac
aliquot
preincub
virusserum
mixtur
plate
incub
overnight
h
unless
note
otherwis
day
two
medium
aspir
cell
wellbywel
one
assay
plate
time
cell
fix
per
well
absolut
ethanol
min
room
temperatur
rehydr
amount
pb
least
min
block
normal
goat
serum
ng
normal
donkey
serum
nd
jackson
immunoresearch
laboratori
inc
west
grove
pa
pb
min
incub
monoclon
antibodi
clone
chemicon
temecula
ca
h
follow
wash
primari
antibodi
dilut
biotinlabel
direct
stain
peroxidas
label
goator
donkeyanti
mous
igg
jackson
immunoresearch
lab
ad
min
follow
addit
hrpavidin
vector
lab
hrpstreptavidin
kpl
step
omit
direct
stain
min
follow
wash
peroxidas
substrat
ad
trueblu
aec
stabledab
histoblack
use
comparison
min
stain
step
assay
plate
wash
time
wash
buffer
pb
borat
buffer
salin
bb
contain
use
micropl
washer
ultrawash
plu
dynex
technolog
chantilli
va
antibodi
hrp
conjug
dilut
strength
casein
blocker
pb
pierc
rockford
il
fixat
stain
wash
carri
room
temperatur
wherea
substrat
prewarm
optim
perform
special
care
taken
prevent
cell
monolay
dri
alcohol
fixat
stain
plate
rins
distil
water
follow
absolut
ethanol
air
dri
store
dark
scan
stain
plate
scan
count
immunospot
analyz
ctl
cellular
technolog
ltd
cleveland
oh
use
red
color
system
replic
data
point
averag
n
rel
cell
infect
hcmv
presenc
nsc
calcul
accord
follow
formula
n
mean
infect
cell
test
mean
infect
cell
negcontrol
neutral
curv
automat
plot
prism
graph
softwar
graphpad
softwar
san
diego
ca
use
curv
fit
constrain
bottom
top
nt
valu
determin
curv
fifti
percent
neutral
titer
nt
ec
prism
defin
midpoint
inflect
point
samplespecif
neutral
curv
program
also
report
good
fit
r
valu
curv
confid
interv
ec
sampl
assay
predilut
nt
equal
ec
multipli
predilut
factor
global
fit
featur
prism
softwar
use
statist
compar
neutral
curv
correspond
ec
nt
valu
two
data
set
optim
final
assay
protocol
use
cell
half
area
micropl
strain
hcmv
input
yield
approxim
infect
cell
per
well
test
control
human
sera
well
fb
use
assay
medium
heatinactiv
assay
medium
supplement
noninactiv
gpsc
provid
exogen
complement
viru
sera
preincub
h
viral
inoculum
left
cell
entir
incub
plate
nsc
includ
refer
infect
psc
control
assay
qualiti
incub
well
block
nd
infect
cell
stain
nuclear
use
follow
addit
biotinyl
donkeyantimous
igg
secondari
antibodi
streptavidinhrp
infect
cell
visual
trueblu
substrat
use
biotinavidin
amplif
peroxidas
signal
gener
compar
four
histochem
peroxidas
substrat
visual
cell
immunostain
mab
although
aec
stabledab
histoblack
produc
stain
nuclear
imag
easili
detect
quantifi
immunospot
analyz
use
trueblu
produc
imag
superior
size
contrast
result
highest
accuraci
sensit
fig
therefor
trueblu
substrat
use
experi
primari
antibodi
test
concentr
rang
lowest
two
gave
highest
sensit
lowest
background
stain
data
shown
work
concentr
primari
antibodi
chosen
studi
secondari
biotinyl
antibodi
test
dilut
rang
highest
assay
sensit
lowest
background
achiev
use
dilut
data
shown
hrpavidin
hrpstreptavidin
use
gave
indistinguish
result
data
shown
sidebysid
test
compar
direct
stain
method
optim
biotinstreptavidinamplifi
stain
procedur
direct
stain
infect
nuclei
result
smaller
averag
spot
size
biotinstreptavidinamplifi
stain
mm
direct
stain
versu
mm
amplifi
stain
yield
smaller
less
precis
nuclear
count
cv
direct
stain
versu
cv
amplifi
stain
requir
much
longer
substrat
reaction
time
min
versu
min
direct
amplifi
stain
respect
base
find
biotinstreptavidinamplifi
stain
procedur
chosen
experi
optim
stain
procedur
routin
yield
low
background
immunospot
analyz
count
virusfre
well
well
infect
cell
data
shown
subtract
background
count
data
analysi
therefor
deem
unnecessari
microneutr
assay
describ
andreoni
et
al
call
preincub
viru
test
sera
follow
incub
virusserum
inoculum
indic
cell
monolay
cell
incub
addit
h
virusfre
medium
modifi
version
assay
viru
sera
preincub
h
virusserum
inoculum
incub
indic
cell
h
schoppel
et
al
klein
et
al
direct
comparison
two
method
virusserum
preincub
time
combin
incub
without
remov
viru
result
far
better
distinct
neutral
nonneutr
sera
virusserum
preincub
time
combin
incub
cell
virusserum
inoculum
remov
fig
result
also
confirm
observ
made
klein
et
al
human
sera
dilut
less
nonspecif
toxic
effect
infect
mimick
neutral
fig
experi
virusserum
preincub
time
follow
incub
use
avoid
nonspecif
inhibit
infect
thu
ensur
high
assay
specif
lowest
dilut
use
assay
human
sera
primarili
reduc
demand
cell
evalu
use
half
area
well
tissu
cultur
micropl
accommod
half
mani
cell
use
half
much
medium
standard
micropl
seen
sidebysid
comparison
acquir
nuclear
imag
larger
better
defin
half
area
well
standard
well
smaller
surfac
area
half
area
well
requir
adjust
camera
len
zoom
closer
cell
result
higher
magnif
fig
standard
well
contain
infect
cell
half
area
well
mean
infect
cell
sd
valu
respect
receiv
twice
mani
plate
cell
twice
fig
hcmvinfect
cell
immunostain
use
differ
commerci
peroxidas
substrat
cell
standard
micropl
infect
viru
h
follow
incub
virusfre
medium
cell
fix
plate
divid
four
segment
stain
nuclear
express
use
ident
biotinavidin
amplifi
procedur
except
substrat
substrat
partial
closeup
imag
repres
well
shown
magnif
b
six
replic
well
cell
seed
standard
micropl
infect
twofold
serial
dilut
h
h
later
stain
use
ident
procedur
except
substrat
dilut
mean
nuclear
count
duplic
data
point
standard
deviat
plot
function
viru
dilut
loglog
scale
viru
input
howev
contrari
expect
nuclear
count
former
also
show
higher
variabl
half
area
well
cv
respect
consequ
higher
variabl
good
fit
neutral
curv
obtain
standard
plate
also
inferior
compar
half
area
plate
albeit
nt
valu
deriv
two
plate
type
compar
within
test
sampl
fig
c
therefor
half
area
micropl
use
experi
uniform
intact
indic
cell
monolay
enabl
optim
infect
accuraci
autom
data
collect
perhap
critic
requir
microneutr
assay
use
autom
data
collect
analysi
evalu
three
commerci
avail
human
embryon
fibroblastlik
cell
line
commonli
use
diagnosi
hcmv
infect
indic
cell
sidebysid
comparison
cell
show
similar
infect
eg
mean
infect
cell
sd
respect
yield
similar
neutral
curv
shown
nt
valu
sever
test
sera
tabl
howev
provid
us
highest
percentag
usabl
assay
plate
fewest
stain
problem
compar
variou
seed
densiti
cell
cellsml
found
plate
cell
cellsml
cell
per
well
half
area
micropl
cell
per
well
standard
micropl
h
assay
consist
work
well
data
shown
furthermor
cell
work
equal
well
whether
use
passag
data
shown
passag
recoveri
frozen
stock
cell
passag
passag
produc
mean
sd
infect
valu
respect
control
well
n
yield
nt
valu
versu
one
test
sampl
nt
valu
versu
anoth
test
sampl
neutral
curv
obtain
use
passag
versu
passag
gener
cell
monolay
found
differ
compar
global
fit
applic
prism
fig
cell
passag
least
twice
time
maximum
passag
number
test
seed
cellsml
use
experi
humor
immun
respons
hcmv
compris
complementdepend
complementindepend
neutral
antibodi
exampl
addit
fresh
guinea
pig
complement
human
sera
obtain
convalesc
hcmv
infect
increas
neutral
titer
fold
schmidt
et
al
addit
exogen
complement
variou
commerci
igg
prepar
shown
enhanc
neutral
hcmv
fold
lewi
et
al
eizuru
et
al
measur
plaquereduct
establish
complement
may
affect
serum
neutral
activ
measur
assay
heatinactiv
test
sampl
wide
rang
neutral
activ
prepar
predilut
pool
fig
comparison
techniqu
virusserum
preincub
infect
cell
neutral
assay
perform
use
standard
micropl
indic
cell
test
sera
volunt
close
symbol
connect
dot
line
repres
five
sera
test
nonreact
open
symbol
connect
solid
line
repres
five
sera
test
reactiv
hcmv
gb
igg
elisa
mean
infect
nuclei
duplic
well
standard
deviat
plot
serum
dilut
viru
sera
preincub
h
cell
expos
virusserum
inoculum
h
follow
incub
fresh
cultur
medium
b
viru
sera
preincub
h
cell
expos
virusserum
inoculum
h
ab
serum
nsc
test
sampl
assay
neutral
activ
without
gpsc
sourc
complement
use
lieu
half
usual
heatinactiv
fb
assay
medium
presenc
gpsc
result
time
greater
nt
valu
absenc
fig
b
presenc
heatinactiv
gp
data
shown
area
well
right
panel
c
micropl
infect
immunostain
use
trueblu
substrat
describ
materi
method
section
plate
type
imag
repres
well
shown
magnif
half
area
well
greater
necess
b
c
shown
five
ab
pool
serum
sampl
predilut
nsc
individu
neutral
curv
fit
prism
correspond
r
valu
deriv
neutral
activ
nt
gpsc
use
studi
hcmvneutral
activ
independ
comparison
maximum
infect
substanti
differ
presenc
gpsc
compar
absenc
valu
mean
infect
nuclei
standard
deviat
neg
control
well
without
gpsc
versu
versu
versu
versu
versu
versu
respect
also
differ
gpsc
gp
mean
number
infect
nuclei
versu
versu
respect
also
clarifi
whether
vari
amount
human
serum
present
medium
assay
result
serial
dilut
sampl
assay
influenc
neutral
activ
measur
simultan
ran
third
version
assay
total
human
serum
content
assay
medium
adjust
constant
ad
heatinactiv
nsc
everi
well
assay
plate
fig
use
global
fit
correspond
neutral
curv
pair
obtain
without
ad
nsc
presenc
gpsc
found
statist
indistinguish
five
test
sampl
data
shown
indic
normal
concentr
human
serum
assay
well
provid
advantag
therefor
assay
medium
contain
inactiv
fb
gpsc
chosen
use
experi
establish
assay
linear
ab
pool
predilut
nsc
provid
test
sera
rang
nt
valu
shown
fig
assay
linear
test
sampl
neutral
activ
rang
nt
valu
extrapol
softwar
program
furthermor
neutral
activ
nt
valu
correl
close
level
antigb
serum
igg
fig
establish
key
perform
characterist
assay
perform
two
oper
run
total
assay
plate
pair
thirteen
separ
assay
use
optim
final
protocol
overal
precis
obtain
test
psc
n
analys
data
shown
accept
cellbas
assay
although
nt
rang
measur
psc
fairli
broad
neutral
curv
psc
consist
good
r
valu
mean
r
assay
accept
cutoff
mean
r
r
data
shown
compar
evalu
r
valu
obtain
sampl
posit
versu
neg
bind
cmv
gb
igg
elisa
wloch
unpublish
data
reveal
good
fit
samplespecif
fig
effect
cell
passag
number
measur
neutral
activ
neutral
activ
two
test
sera
measur
two
simultan
ran
assay
use
indic
cell
passag
p
squar
versu
p
triangl
two
neutral
curv
obtain
two
test
sampl
compar
use
global
fit
individu
fit
curv
repres
dot
line
global
fit
share
curv
repres
solid
line
correspond
nt
valu
also
shown
five
test
sera
analyz
neutral
activ
ident
condit
except
use
cell
indic
monolay
assay
run
start
dilut
sera
nt
valu
test
sampl
determin
use
constrain
curv
fit
neutral
curv
obtain
use
three
indic
cell
strain
compar
use
global
fit
prism
neutral
curv
decis
paramet
distinguish
neutral
nonneutr
test
sampl
neutral
assay
mean
r
valu
test
sampl
posit
antigb
antibodi
elisa
cutoff
n
analys
data
shown
sharp
contrast
sampl
neg
antigb
igg
poorli
fit
neutral
curv
mean
r
valu
mean
cutoff
valu
n
analys
data
shown
therefor
r
valu
sampl
use
key
criterion
determin
whether
sampl
neutral
activ
sampl
r
valu
equal
greater
nt
valu
least
deem
posit
r
valu
deem
neg
cmvneutral
activ
fig
assay
linear
relationship
cmvneutral
activ
serum
antigb
igg
level
pool
ab
serum
twofold
serial
predilut
nsc
obtain
multipl
test
sampl
decreas
neutral
activ
assay
neutral
activ
measur
nt
valu
plot
expect
nt
valu
express
percentag
potent
sampl
assay
linear
regress
analysi
indic
high
degre
correl
expect
measur
nt
valu
experi
r
valu
b
neutral
activ
valu
rang
plot
correspond
antigb
igg
elisa
titer
rang
total
analys
linear
regress
analysi
show
strong
posit
correl
r
neutral
activ
nt
valu
antigb
igg
titer
fig
effect
complement
total
human
serum
content
neutral
activ
five
test
sampl
pool
ab
serum
predilut
nsc
assay
neutral
activ
medium
contain
fb
fb
human
sera
heatinactiv
b
test
sampl
assay
medium
contain
heatinactiv
fb
gpsc
c
test
sampl
assay
medium
contain
heatinactiv
fb
gpsc
heatinactiv
nsc
ad
equal
human
serum
content
nt
valu
extrapol
softwar
sampl
r
valu
least
nt
valu
report
reactiv
sera
r
valu
reassay
consid
reactiv
r
valu
repeat
assay
least
otherwis
sampl
deem
nonreact
sera
antigb
igg
titer
greater
assay
sensit
detect
neutral
activ
nt
least
tabl
result
sera
low
antigb
igg
titer
sera
hcmv
dna
vaccin
trial
test
neg
diamedix
hcmv
igg
elisa
posit
vical
antigb
igg
elisa
variabl
sera
low
antigb
igg
titer
posit
reactiv
assay
sera
antigb
igg
titer
one
antigb
titer
nonreact
neg
assay
result
suggest
neutral
assay
sensit
even
low
level
antigb
antibodi
assay
show
specif
antigb
igg
neg
sera
assay
test
nonreact
one
sampl
prompt
reassay
r
valu
first
analysi
develop
fast
conveni
sensit
specif
microneutr
assay
hcmv
enabl
highthroughput
assess
neutral
antibodi
respons
hcmv
vaccin
candid
ongo
futur
clinic
trial
includ
test
vical
pdna
vaccin
previous
describ
other
andreoni
et
al
micropl
format
use
measur
infect
base
immunostain
iea
howev
replac
immunofluoresc
stain
sensit
immunohistochem
procedur
enabl
autom
data
acquisit
analysi
assay
potenti
measur
neutral
hcmv
strain
includ
clinic
isol
littl
procedur
modif
indirect
immunoperoxidas
stain
use
antiiea
mab
dab
substrat
employ
detect
diagnos
hcmv
infect
sever
year
develop
immunofluoresc
microneutr
assay
swenson
kaplan
similar
detect
method
also
use
combin
substrat
aec
titer
hcmv
measur
neutral
antibodi
chou
scott
later
immunofluoresc
microassay
also
modifi
immunohistochem
stain
substrat
dab
use
measur
neutral
rhesu
cmv
macaqu
serum
lockridg
et
al
altern
other
use
modifi
andreoni
assay
aec
quantit
neutral
antibodi
sera
mice
vaccin
dens
bodi
pepperl
et
al
approach
nuclear
imag
count
analyst
use
microscop
recogn
need
autom
data
acquisit
analyz
larg
number
specimen
prospect
clinic
trial
wang
et
al
use
micropl
spectrophotomet
measur
fluoresc
emit
cell
infect
egfpexpress
recombin
town
toledo
strain
hcmv
version
hcmv
microneutr
assay
altern
use
digit
camera
captur
fluoresc
imag
imag
process
softwar
data
analysi
howev
neutral
assay
base
intrins
fluoresc
limit
avail
appropri
hcmv
recombin
furthermor
minimum
postinfect
cultiv
time
need
cell
produc
signal
quantifi
micropl
spectrophotometri
edg
effect
made
outer
well
micropl
useless
assay
wang
et
al
andreoni
et
al
also
report
outermost
column
row
yield
uninterpret
result
microassay
thu
use
evapor
barrier
phenomenon
may
specif
fluoresc
detect
assay
use
well
micropl
howev
strateg
posit
control
test
sampl
across
plate
minim
potenti
influenc
well
locat
result
autom
elispot
analyz
convent
use
scan
count
color
immunoprecipit
opaqu
white
membranebottom
micropl
manufactur
specif
use
elispot
assay
total
test
sera
variou
antigb
igg
level
analyz
neutral
activ
use
optim
neutral
assay
sera
classifi
neutral
activ
describ
section
cheong
et
al
use
elispot
approach
titer
stock
recombin
viru
express
human
plate
infect
cell
onto
ab
coat
elispot
plate
novel
applic
neutral
assay
sar
coronaviru
elispot
analyz
use
count
whole
cell
actual
grow
elispot
plate
membran
infect
pseudoviru
also
encod
lac
z
gene
made
cell
blue
upon
stain
xgal
han
et
al
hcmv
microneutr
assay
appear
first
use
autom
elispot
analyz
quantit
immunostain
cell
nuclei
experi
use
elispot
plate
purpos
unnecessari
increas
assay
expens
studi
compar
sever
micropl
type
includ
multiscreenha
cellulos
ester
multiscreenip
high
protein
bind
hydrophob
immobilonp
elispot
plate
millipor
burlington
neither
ha
cellulos
ester
elispot
plate
white
opaqu
tissu
cultur
plate
perkinelm
boston
show
advantag
standard
clear
tissu
cultur
plate
nunc
data
shown
employ
autom
elispot
analyz
made
count
stain
nuclei
conveni
also
less
prone
human
error
thu
object
result
indic
curv
fit
data
accuraci
sensit
assay
improv
increas
viral
load
critic
assay
sera
littl
neutral
activ
immunospot
analyz
count
whole
micropl
thousand
stain
nuclei
well
half
hour
assay
easili
run
high
viral
input
high
level
accuraci
hcmv
neutral
assay
use
primari
human
foreskin
fibroblast
hff
indic
monolay
regardless
whether
endpoint
base
plaquereduct
gonczol
et
al
adler
et
al
pass
et
al
immunostain
viral
protein
target
cell
chou
scott
andreoni
et
al
klein
et
al
lockridg
et
al
pepperl
et
al
human
embryon
fibroblastlik
cell
long
use
interchang
primari
fibroblast
detect
hcmv
cell
cultur
swenson
kaplan
even
found
superior
hff
shorter
h
versu
h
cultur
gleav
meyer
late
cell
use
neutral
assay
well
wang
et
al
hand
cell
perform
inconsist
indic
monolay
neutral
analysi
although
readili
infect
express
protein
qualiti
monolay
vari
larg
unpredict
togeth
extent
background
stain
affect
autom
data
acquisit
detriment
data
shown
prompt
report
show
hel
cell
line
primari
hff
equal
reliabl
overal
sensit
specif
detect
hcmv
urin
use
variou
clinic
laboratori
demmler
et
al
compar
cell
line
assay
although
three
cell
line
could
infect
equal
well
yield
compar
neutral
activ
valu
sever
test
sera
cultur
stain
characterist
cell
much
better
cell
cell
provid
uniform
indic
monolay
hardier
cell
ultim
improv
robust
assay
studi
switch
standard
clear
tissu
cultur
micropl
clear
tissu
cultur
plate
whose
well
half
area
standard
plate
cell
avail
potenti
bottleneck
want
reduc
cell
requir
thu
abl
increas
number
assay
plate
could
run
found
half
area
plate
benefici
multipl
level
requir
fewer
cell
also
less
reagent
viru
regular
plate
yield
better
data
appar
superior
half
area
plate
standard
plate
assay
like
combin
result
indic
cell
monolay
shelter
less
disturb
necessari
manipul
assay
nuclear
imag
like
count
accur
half
area
plate
requir
scan
count
higher
magnif
standard
micropl
make
nuclear
imag
better
defin
approach
measur
viral
infect
use
elispot
analyz
potenti
use
adapt
varieti
applic
among
other
great
help
develop
neutral
assay
virus
highthroughput
screen
desir
clinic
trial
set
easili
modifi
titrat
variou
virus
recombin
develop
screen
assay
antivir
agent
